Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CKS1B | P61024 | 1/20 | 0.35 |
| ▸ | SKP1 | P63208 | 1/20 | 0.35 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.35 |
| ▸ | APP | P05067 | 1/20 | 0.30 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL46324 | 0.72 | MEN1 (0.37) | CKS1BSKP1SKP2APPKCNH2 | |
| SCHEMBL11625025 | 0.70 | NOS3 (0.41) | CKS1BSKP1SKP2 | |
| SCHEMBL26542430 | 0.70 | KCNH2 (0.37) | CKS1BSKP1SKP2APPKCNH2 | |
| SCHEMBL6345318 | 0.70 | MEN1 (0.35) | CKS1BSKP1SKP2APPKCNH2 | |
| SCHEMBL12186835 | 0.70 | APP (0.37) | CKS1BSKP1SKP2APPKCNH2 | |
| SCHEMBL159830 | 0.70 | CKS1B (0.35) | CKS1BSKP1SKP2APPKCNH2 | |
| SCHEMBL30756137 | 0.70 | CKS1B (0.35) | CKS1BSKP1SKP2APPKCNH2 | |
| SCHEMBL9925945 | 0.68 | CKS1B (0.34) | CKS1BSKP1SKP2KCNH2 | |
| Trimethylammonium SCHEMBL27912435 | 0.68 | NOS3 (0.34) | — | |
| SCHEMBL9924592 | 0.67 | CKS1B (0.33) | CKS1BSKP1SKP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160207918-A1 | SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2016-07-21 | — | — | US | disclosed |
| US-20160152615-A1 | PRODRUGS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2016-06-02 | — | — | US | disclosed |
| US-20160075703-A1 | SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2016-03-17 | — | — | US | disclosed |
| US-20150329543-A1 | PRODRUGS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2015-11-19 | — | — | US | disclosed |
| US-20150259342-A1 | SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2015-09-17 | — | — | US | disclosed |
| US-20150087652-A1 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2015-03-26 | — | — | US | disclosed |
| US-20140135342-A1 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2014-05-15 | — | — | US | disclosed |
| US-20130289046-A1 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2013-10-31 | — | — | US | disclosed |
| US-20130030005-A1 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-01-31 | — | — | US | disclosed |
| EP-1363705-B9 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2012-11-07 | — | — | EP | disclosed |
| US-20080119480-A1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY | 2008-05-22 | — | — | US | disclosed |
| US-7354924-B2 | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-04-08 | — | — | US | disclosed |
| EP-1549313-A1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | Bristol-Myers Squibb Company (US) | 2005-07-06 | — | — | EP | disclosed |
| US-20050090522-A1 | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2005-04-28 | — | — | US | disclosed |
| US-20040110785-A1 | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2004-06-10 | — | — | US | disclosed |
| WO-2004014380-A1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-02-19 | — | — | WO | disclosed |
| EP-1363705-A1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-11-26 | — | — | EP | disclosed |
| US-20030207910-A1 | Treatment of HIV and AIDS | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2003-11-06 | — | — | US | disclosed |
| US-20030069266-A1 | Aids therapy | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2003-04-10 | — | — | US | disclosed |
| WO-2002062423-A1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-08-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152615-A1 | PRODRUGS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | ITPA, IMPDH2, IDO1 | CKS1B 3000/4885SKP1 2615/4885SKP2 784/4885 |
| US-20130030005-A1 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | PREP, PEPD, DNPEP | CKS1B 2681/4885SKP1 1898/4885SKP2 646/4885 |
| US-20040110785-A1 | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives | ITPA, IDO1, IDO2 | CKS1B 3053/4885SKP1 2920/4885SKP2 975/4885 |
| US-20160075703-A1 | SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | ITPA, IDO1, IDO2 | CKS1B 3574/4885SKP1 2865/4885SKP2 831/4885 |
| US-20030069266-A1 | Aids therapy | ENTPD5, CCR5, ITPA | CKS1B 3054/4885SKP1 4110/4885SKP2 1453/4885 |
| US-20130289046-A1 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | PREP, PEPD, DNPEP | CKS1B 2681/4885SKP1 1898/4885SKP2 646/4885 |
| US-20150087652-A1 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | PREP, PEPD, DNPEP | CKS1B 2681/4885SKP1 1898/4885SKP2 646/4885 |
| US-20140135342-A1 | PHARMACEUTICAL FORMULATIONS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | PREP, PEPD, DNPEP | CKS1B 2681/4885SKP1 1898/4885SKP2 646/4885 |
| US-20150329543-A1 | PRODRUGS OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | ITPA, IMPDH2, IDO1 | CKS1B 3000/4885SKP1 2615/4885SKP2 784/4885 |
| US-20050090522-A1 | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives | ITPA, IDO1, IDO2 | CKS1B 3053/4885SKP1 2920/4885SKP2 975/4885 |
| US-20080119480-A1 | COMPOSITION AND ANTIVIRAL ACTIVITY OF SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | ITPA, IDO1, IDO2 | CKS1B 3053/4885SKP1 2920/4885SKP2 975/4885 |
| US-20150259342-A1 | SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | ITPA, IDO1, IDO2 | CKS1B 3574/4885SKP1 2865/4885SKP2 831/4885 |
| US-20160207918-A1 | SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES WITH PROTEASE INHIBITORS | PREP, PEPD, DNPEP | CKS1B 2483/4885SKP1 2243/4885SKP2 544/4885 |
| US-20030207910-A1 | Treatment of HIV and AIDS | CD4, CCR5, IDO1 | CKS1B 3352/4885SKP1 3605/4885SKP2 1890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.